JAK Inhibitors, Anti-IL-6R Antagonists, Secukinumab, Abatacept, and Rituximab in Polymyalgia Rheumatica: What Insights Emerge from Phase 2 and 3 Randomized Controlled Trials?

Background

Glucocorticoids (GCs) remain the cornerstone of polymyalgia rheumatica (PMR) management, but their cumulative toxicity necessitates effective GC-sparing strategies. Recent randomized controlled trials (RCTs) evaluating targeted therapies with diverse mechanisms of action have offered an unprecedented opportunity to dissect the disease’s underlying immunobiological architecture.